Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
21:27:15 EDT Thu 03 Oct 2024
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:MYGN - MYRIAD GENETICS INC - http://www.myriad.com/
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
MYGN - Q0.125.58·27.400.126.43-0.53-2.0378.19,7594,67726.77  27.26  26.4029.30  13.8216:29:4809:0015 min RT 2¢

Recent Trades - Last 10 of 4677
Time ETExPriceChangeVolume
16:29:48Q26.43-0.534,650
16:04:29Q26.43-0.53169
16:02:28Q26.43-0.531
16:02:10Q26.43-0.53410
16:01:52Q26.43-0.533,624
16:01:38Q26.43-0.53100
16:01:18Q26.43-0.531,930
16:01:06Q26.43-0.5338
16:01:02Q26.43-0.53127
16:00:39Q26.43-0.53172

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-10-03 09:00U:MYGNNews ReleaseMyriad Genetics and Ultima Genomics to Explore the UG 100(TM) Sequencing Platform to Advance Clinical Test Offerings in Oncology and Reproductive Genomics
2024-10-01 16:05U:MYGNNews ReleaseMyriad Genetics Announces Third Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
2024-09-18 08:00U:MYGNNews ReleaseMyriad Genetics to Share New Data Highlighting Genetic Testing Advancements at 2024 National Society of Genetic Counselors Annual Conference
2024-09-05 08:00U:MYGNNews ReleaseMyriad Genetics to Host Investor Event on October 9, 2024
2024-08-21 08:00U:MYGNNews ReleaseMyriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences
2024-08-06 16:05U:MYGNNews ReleaseMyriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%
2024-08-01 16:05U:MYGNNews ReleaseMyriad Genetics Advances International Reorganization and Completes Sale of EndoPredict Business to Eurobio Scientific
2024-07-31 08:50U:MYGNNews ReleaseMyriad Genetics Appoints Jennifer Fox as Chief Legal Officer
2024-07-30 08:00U:MYGNNews ReleaseMyriad Genetics to Release Second Quarter 2024 Financial Results on August 6, 2024
2024-07-17 08:00U:MYGNNews ReleaseWhat We Don't Know Can Hurt: New Cancer Risk Survey from Myriad Genetics Reveals Serious Knowledge Gaps About Breast Density and Cancer Risk
2024-07-11 09:00U:MYGNNews ReleaseMyriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing
2024-07-09 09:00U:MYGNNews ReleaseMyriad Genetics Announces Second Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
2024-07-02 09:00U:MYGNNews ReleaseMyriad Genetics Earns 2024 Great Place To Work(TM) Certification(TM)
2024-06-24 16:05U:MYGNNews ReleaseSurvey Suggests Increased Attention on Mental Health Warranted in the Run-Up to the Election
2024-06-11 08:00U:MYGNNews ReleaseMyriad Genetics Collaborates with GSK to Improve Access to HRD Testing in 9 Countries
2024-06-04 09:00U:MYGNNews ReleaseMyriad Genetics Launches New Universal Plus Panel for Foresight(TM) Carrier Screen
2024-06-03 16:05U:MYGNNews ReleaseGenetics in Medicine Publishes Myriad Genetics Patient-Outcomes Study Validating RiskScore(TM) as a Clinical Breast Cancer Risk Assessment Tool
2024-05-30 17:56U:MYGNNews ReleaseQIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications
2024-05-23 18:00U:MYGNNews ReleaseMyriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO(TM) Annual Meeting
2024-05-16 16:05U:MYGNNews ReleaseNew Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer